Perspective Therapeutics (CATX) vs Journey Medical (DERM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Journey Medical (DERM) has outperformed Perspective Therapeutics (CATX) over the past year, losing 55.8% versus a loss of 63.9%. Over five years, DERM leads with a -61.1% price change compared with -84.6% for CATX. Journey Medical is the larger company by market cap ($93.2 million vs $91.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | DERM |
|---|---|---|
| Share price | $0.7538 | $3.30 |
| Market cap | $91.03M | $93.16M |
| 1-day change | -3.85% | -7.04% |
| YTD return | -72.59% | -57.20% |
| 1-year return | -63.93% | -55.76% |
| 5-year return | -84.62% | -61.13% |
| EPS (TTM) | $-1.25 | $-0.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $61.86M |
| Revenue growth (YoY) | — | +10.20% |
| Net income (latest FY) | $-103.12M | $-11.43M |
| Gross margin | — | 66.17% |
| Operating margin | — | -13.21% |
| Net margin | — | -18.48% |
| 52-week high | $6.16 | $9.56 |
| 52-week low | $0.73 | $3.21 |
| Distance from 52-week high | -87.76% | -65.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1188.14% | +286.36% |
| Average volume | 2.70M | 190.39K |
| Shares outstanding | 120.76M | 22.23M |
| Employees | 163 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
CATX vs DERM FAQ
Which is bigger, Perspective Therapeutics or Journey Medical?
Journey Medical (DERM) is larger, with a market capitalization of $93.16M compared with $91.03M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or DERM?
DERM returned -55.76% over the past 12 months, compared with -63.93% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Journey Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.